Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. (SUPN) Stock Overview
Explore Supernus Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
2.9B
P/E Ratio
-75.09
EPS (TTM)
$-0.68
ROE
-0.04%
SUPN Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Supernus Pharmaceuticals, Inc. (SUPN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 48.27, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $58.36.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -75.09 and a market capitalization of 2.9B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.